OncoMed Pharmaceuticals, a biopharma company developing anti-cancer therapeutics, will cut its workforce by approximately 50% in an effort to focus on advancing three clinical-stage programs and continue immuno-oncology drug discovery and development. The company is seeking to partner select pipeline assets.  The workforce reduction will result in 64 remaining full-time employees. OncoMed expects to realize cost savings of approximately $60 million over the next two years and anticipates havi...